Cytosorbents Corp (CTSO)

• Market cap: $50.3M
• 1 day: 3.99%
• 5 days: -15.28%
• 1 month: -0.10%
• 3 months: -40.97%
• 6 months: 15.71%
• Year to date: -14.49%
• 1 year: -50.27%
• 5 years: -76.60%
• 10 years: -89.06%
• Sector: Healthcare
• Industry: Surgical & Medical Instruments & Apparatus

About: CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales, Distributors/strategic partners, and Government segments. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.

Employees: 186

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

109% more capital invested

Capital invested by funds: $11.8M [Q2] → $24.6M (+$12.8M) [Q3]

50% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 6

6% more funds holding

Funds holding: 49 [Q2] → 52 (+3) [Q3]

0.6% less ownership

Funds ownership: 30.78% [Q2] → 30.18% (-0.6%) [Q3]

38% less repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 13

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $1 9% upside
• Avg. target: $7 665% upside
• High target: $10 993% upside

3 analyst ratings

• positive: 2 67%
• neutral: 1 33%
• negative: 0 0%

D. Boral Capital Jason Kolbert 25% 1-year accuracy 38 / 150 met price target	993% upside $10	Buy Maintained	12 Nov 2024
HC Wainwright & Co. Sean Lee 60% 1-year accuracy 12 / 20 met price target	9% upside $1	Neutral Reiterated	11 Nov 2024
EF Hutton Jason Kolbert 25% 1-year accuracy 38 / 150 met price target	993% upside $10	Buy Maintained	8 Nov 2024